Genome Publications
https://doi.org/10.61096/978-81-981372-2-7_13

Chapter 13

Dermatologic Therapeutics

Dr. Shaktiprasad Pradhan
Professor and Principal, KRIMS, Bhubaneswar, Odisha
Dr. Suchismita Subadini
Research Associate, Department of Chemistry, NIT Rourkela, Odisha
Pradyumna Kumar Behera
Research scientist-1, AIIMS, Bhubaneswar, Odisha

Abstract: Dermatologic therapeutics represents one of the most rapidly evolving areas in modern pharmacology, integrating topical, systemic, and biologic treatment modalities to address both acute and chronic skin disorders. The unique barrier function of the skin, particularly the stratum corneum, creates challenges for drug delivery that necessitate innovative formulations and delivery technologies. This chapter provides a comprehensive overview of the pharmacological management of common dermatological conditions, including psoriasis, atopic dermatitis, acne, seborrheic disorders, and infectious skin diseases. Topical therapies, ranging from corticosteroids and retinoids to antimicrobials, remain first-line approaches for localized disease, while systemic immunomodulators such as methotrexate, cyclosporine, and apremilast are employed in refractory or extensive disease. Advances in biologics, particularly anti-TNF, IL-17, IL-23 inhibitors, and dupilumab, have revolutionized the management of psoriasis and atopic dermatitis, offering targeted, durable responses. Acne therapeutics include hormonal therapies, isotretinoin, and carefully regulated antibiotic use, with growing emphasis on antimicrobial stewardship to prevent resistance. The chapter also explores antifungal and antiviral dermatologic agents, transdermal and microneedle-based delivery innovations, and safety monitoring in dermato-pharmacology. In addition, cosmetic and aesthetic pharmacology, including botulinum toxin, dermal fillers, and cosmeceuticals, is discussed as a growing field at the intersection of dermatology and pharmacotherapy. Future directions highlight nanotechnology, personalized medicine, and pharmacovigilance frameworks as essential for optimizing safety, efficacy, and patient satisfaction in dermatologic therapeutics.

Keywords: dermatology, topical therapy, biologics, transdermal delivery, cosmetic pharmacology

Citation: Shaktiprasad Pradhan, Suchismita Subadini, Pradyumna Kumar Behera. Dermatologic Therapeutics. ***Modern Therapeutic Pharmacology: Precision Therapeutics Across Organ Systems*****. 2025; Pp134-143.** https://doi.org/10.61096/978-81-981372-2-7_13

13.0 INTRODUCTION

Dermatologic therapeutics has emerged as a dynamic and complex domain in pharmacology due to the unique challenges posed by the anatomy and physiology of the skin. The skin, as the largest organ of the human body, functions primarily as a protective barrier against environmental insults, pathogens, and chemical agents, while simultaneously regulating water loss, thermoregulation, and immune surveillance. This barrier, primarily localized within the stratum corneum, presents one of the most formidable challenges to effective drug delivery. Lipophilicity, molecular size, and degree of ionization are among the critical determinants of a drug's ability to penetrate the cutaneous barrier. Consequently, many dermatologic formulations require specialized excipients, permeation enhancers, or innovative delivery systems to ensure adequate bioavailability at the site of action [1,2].

Dermatologic drug delivery strategies must reconcile two conflicting requirements: achieving sufficient penetration into deeper skin layers while maintaining safety and minimizing systemic exposure. These limitations explain why dermatologic pharmacotherapy has historically relied heavily on topical formulations, which allow high local concentrations of active compounds with relatively low systemic toxicity. Despite this advantage, topical administration is limited in cases of severe, extensive, or refractory disease, necessitating the use of systemic agents or biologics.

In recent decades, the burden of dermatologic diseases has increased worldwide, with conditions such as psoriasis, atopic dermatitis, and acne accounting for a significant proportion of outpatient consultations. These disorders not only cause physical morbidity but also have profound psychosocial impacts, often impairing quality of life, self-esteem, and productivity. Thus, therapeutic approaches in dermatology must balance efficacy, long-term safety, and patient adherence [3].

Emerging technologies, including nanocarriers, microneedles, and vesicular drug delivery systems, are currently being investigated to improve cutaneous bioavailability and therapeutic targeting. Furthermore, the rise of biologic therapies and small-molecule immunomodulators has transformed the therapeutic landscape of inflammatory dermatoses. Alongside these advancements, dermato-pharmacovigilance has gained importance, given the long-term use of immunosuppressants and biologics, which necessitate robust monitoring of adverse events and hypersensitivity reactions [4].

This chapter explores the pharmacology of dermatologic therapeutics in a structured manner, beginning with an overview of the pathophysiology of common skin disorders, progressing through topical and systemic therapies, biologics, antifungal and antiviral agents, and concluding with delivery innovations, safety considerations, and cosmetic pharmacology.

13.1 Pathophysiology of Common Skin Disorders

Understanding the pathophysiology of common dermatological disorders is fundamental to appreciating their therapeutic management. Skin diseases such as psoriasis, atopic dermatitis, acne, and superficial fungal infections share overlapping inflammatory mechanisms but diverge in molecular triggers and clinical manifestations. Psoriasis is a chronic, immune-mediated disorder characterized by hyperproliferation of keratinocytes, angiogenesis, and infiltration of activated T cells. The IL-23/Th17 axis plays a pivotal role, with IL-17A and IL-22 driving keratinocyte proliferation and neutrophil recruitment. This results in thick, erythematous plaques covered by silvery scales.

Genetic predisposition, particularly HLA-Cw6, and environmental triggers such as infections or stress contribute to disease onset [5]. Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition associated with immune dysregulation, skin barrier dysfunction, and microbial imbalance.

Mutations in the filaggrin gene compromise barrier integrity, increasing transepidermal water loss and allergen penetration. Th2 cytokines such as IL-4 and IL-13 drive inflammation and pruritus, making AD both an immunologic and barrier defect disorder [6].

Acne vulgaris is a multifactorial disease of the pilosebaceous unit. Excess sebum production, follicular hyperkeratinization, colonization with *Cutibacterium acnes*, and inflammatory responses combine to produce comedones, papules, pustules, and nodules. Androgen hormones exacerbate sebaceous gland activity, explaining the benefit of hormonal therapy in certain cases [7]. Fungal infections of the skin, such as dermatophytosis, result from superficial colonization by fungi that digest keratin.

The host immune response, particularly cell-mediated immunity, plays a critical role in controlling infection. However, recurrent infections are common in immunocompromised individuals, requiring prolonged antifungal therapy [8]. These disorders illustrate the interplay between barrier function, immune dysregulation, and microbial colonization. Therapeutics in dermatology therefore target both symptoms and underlying pathophysiological pathways, ranging from keratolysis and barrier repair to cytokine blockade and antimicrobial therapy.

13.2 Topical Therapies

Topical therapies represent the cornerstone of dermatologic treatment and remain first-line options for most skin diseases due to their ability to deliver drugs directly to the site of pathology. Their advantages include targeted action, reduced systemic exposure, and the ability to formulate a wide range of agents, from anti-inflammatory corticosteroids to retinoids and antimicrobials. Corticosteroids remain the most widely prescribed topical agents in dermatology. By binding glucocorticoid receptors, they suppress pro-inflammatory cytokines, reduce vascular permeability, and inhibit immune cell infiltration. Topical corticosteroids are classified into potency categories ranging from mild (e.g., hydrocortisone) to superpotent (e.g., clobetasol propionate).

Their clinical utility spans psoriasis, eczema, lichen planus, and allergic contact dermatitis. However, prolonged use may lead to skin atrophy, striae, and hypothalamic–pituitary–adrenal axis suppression, necessitating judicious application and monitoring [9]. Calcineurin inhibitors such as tacrolimus and pimecrolimus act by blocking T-cell activation and cytokine release. Unlike corticosteroids, they do not cause skin atrophy, making them particularly valuable for sensitive areas such as the face, eyelids, and intertriginous regions.

They are approved for atopic dermatitis and are often used as steroid-sparing agents [10]. Topical retinoids, including tretinoin, adapalene, and tazarotene, normalize follicular keratinization, reduce sebum production, and exert anti-inflammatory effects. They form the backbone of acne therapy but are also used in photoaging and psoriasis. Adverse effects such as irritation and photosensitivity often limit their use, though newer formulations with polymeric delivery systems have improved tolerability [11].

Topical antimicrobials such as mupirocin, fusidic acid, and clindamycin are widely used in superficial bacterial infections and acne. Resistance, however, is an emerging concern, particularly with indiscriminate use of topical antibiotics. Combined therapies, such as benzoyl peroxide with clindamycin, reduce resistance risk by exerting bactericidal and comedolytic effects [12]. Other topical agents include coal tar, salicylic acid, and vitamin D analogues such as calcipotriol, which inhibit keratinocyte proliferation in psoriasis. Emollients and barrier repair creams remain adjuncts in almost all dermatologic conditions, highlighting the importance of non-pharmacologic strategies in restoring skin barrier integrity.

13.3 Systemic Immunomodulators

When topical therapies fail or disease severity warrants systemic treatment, immunomodulators are introduced. Methotrexate, cyclosporine, and newer small molecules such as apremilast have long-standing roles in the management of refractory psoriasis, atopic dermatitis, and other immune-mediated dermatoses. Methotrexate, a folate antagonist, exerts immunosuppressive and anti-inflammatory effects by inhibiting dihydrofolate reductase and adenosine metabolism. It has been a cornerstone in psoriasis management for decades, with additional benefits in psoriatic arthritis. Monitoring is essential due to risks of hepatotoxicity, bone marrow suppression, and pulmonary toxicity [13].

Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription. It provides rapid relief in severe psoriasis and atopic dermatitis but is limited to short-term use due to nephrotoxicity and hypertension. Monitoring of renal function and blood pressure is critical during therapy [14]. Apremilast, an oral phosphodiesterase-4 (PDE4) inhibitor, reduces the production of pro-inflammatory cytokines such as TNF-α, IL-17, and IL-23. Approved for psoriasis and psoriatic arthritis, it offers an alternative for patients intolerant to methotrexate or biologics. Gastrointestinal adverse effects and weight loss are notable concerns [15].

These systemic immunomodulators are generally reserved for moderate-to-severe disease and require careful patient selection, baseline screening, and ongoing monitoring. Their place in therapy is now being reshaped by the advent of biologic agents, which offer targeted cytokine inhibition with potentially improved safety and efficacy.

13.4 Biologic Therapies for Psoriasis and Eczema

Biologic therapies have transformed the therapeutic landscape of chronic inflammatory skin disorders such as psoriasis and atopic dermatitis. Unlike traditional systemic immunosuppressants, biologics are targeted agents designed to inhibit specific cytokines or immune pathways central to disease pathophysiology. Their introduction has significantly improved efficacy, durability of response, and patient quality of life, albeit with high costs and the need for long-term safety monitoring.

In psoriasis, tumor necrosis factor-alpha (TNF-α) inhibitors such as etanercept, infliximab, and adalimumab were among the first biologics approved. By neutralizing TNF-α, these drugs reduce keratinocyte proliferation, angiogenesis, and T-cell infiltration. While effective, their use has been associated with increased risk of infections, demyelinating diseases, and paradoxical psoriasis in rare cases [16].

The development of interleukin (IL) inhibitors has shifted the focus toward the IL-23/Th17 pathway, now recognized as a key driver of psoriatic inflammation. IL-17 inhibitors, including secukinumab, ixekizumab, and brodalumab, provide rapid clearance of psoriatic plaques with high rates of complete or near-complete remission. Similarly, IL-23 inhibitors such as guselkumab, risankizumab, and tildrakizumab target upstream cytokines, offering durable efficacy and improved dosing convenience, with injections required only every 8–12 weeks [17].

In atopic dermatitis, dupilumab, an IL-4 receptor alpha antagonist, was the first biologic to gain approval. By inhibiting both IL-4 and IL-13 signaling, it directly addresses the Th2-skewed immune response and barrier dysfunction in AD. Clinical trials have demonstrated significant reductions in pruritus, eczema severity, and improved sleep quality. Dupilumab's safety profile is favorable, with conjunctivitis and injection-site reactions being the most common adverse effects [18].

Ongoing research is evaluating other biologics for AD, such as lebrikizumab and tralokinumab (IL-13 inhibitors), as well as JAK inhibitors used orally or topically. These therapies represent an

evolving paradigm of precision immunomodulation in dermatology. Despite their promise, challenges include high costs, limited availability in low-resource settings, and the need for long-term pharmacovigilance.

13.5 Acne and Seborrheic Disorders

Acne vulgaris and seborrheic dermatitis are two of the most prevalent dermatologic conditions, often overlapping in adolescence and young adulthood. Their management requires a nuanced approach balancing antimicrobial efficacy, hormonal modulation, and long-term safety. Acne therapy is stratified by severity. For mild acne, topical retinoids and benzoyl peroxide are first-line agents, with or without topical antibiotics. Moderate-to-severe acne often requires systemic therapy, including oral antibiotics, hormonal agents, or isotretinoin.

Oral isotretinoin remains the gold standard for severe, nodulocystic acne. As a vitamin A derivative, it reduces sebaceous gland activity, normalizes follicular keratinization, and has anti-inflammatory effects. Long-term remission is common, though monitoring is essential due to risks of teratogenicity, hepatotoxicity, hyperlipidemia, and mood alterations. Rigorous pregnancy prevention programs are mandatory during isotretinoin therapy [19]. Hormonal therapy is especially effective in female patients with acne associated with hyperandrogenism or premenstrual flares. Combined oral contraceptives containing ethinylestradiol with progestins, and anti-androgens such as spironolactone, reduce sebum production and improve inflammatory lesions. Monitoring for thromboembolic risk is critical when prescribing oral contraceptives [20].

The role of antibiotics in acne management is now tempered by concerns over resistance. Oral tetracyclines (doxycycline, minocycline) and macrolides are effective but should be prescribed for limited durations and in combination with benzoyl peroxide to mitigate resistance. Dermatology guidelines increasingly emphasize antimicrobial stewardship to preserve efficacy for future generations [21].

Seborrheic dermatitis is a chronic inflammatory condition linked to *Malassezia* yeast overgrowth and sebaceous gland activity. Topical antifungal agents such as ketoconazole, ciclopirox, and selenium sulfide remain the mainstay of therapy. Low-potency corticosteroids or calcineurin inhibitors are added for inflammation control. In resistant cases, systemic antifungals such as itraconazole may be required [22]. Together, acne and seborrheic disorders underscore the importance of personalized therapy, balancing efficacy, safety, and resistance prevention in dermatologic pharmacology.

13.6 Antifungal and Antiviral Dermatologic Agents

Infectious skin diseases caused by fungi and viruses represent a significant burden globally, particularly in tropical climates and immunocompromised populations. Pharmacotherapy relies on both topical and systemic agents, tailored to the extent and severity of infection. Topical antifungal agents such as terbinafine, clotrimazole, and ketoconazole are widely used for localized dermatophytosis and candidiasis. They act by disrupting fungal cell membrane integrity through ergosterol synthesis inhibition. Among systemic antifungals, oral terbinafine and itraconazole are highly effective for extensive or refractory infections.

Terbinafine accumulates in keratinized tissues, making it ideal for onychomycosis, while itraconazole provides broad-spectrum coverage against dermatophytes and yeasts [23]. However, hepatotoxicity and drug–drug interactions are notable limitations requiring liver function monitoring. Antiviral dermatologic agents primarily target herpes simplex virus (HSV) and varicella-zoster virus

(VZV). Acyclovir, valacyclovir, and famciclovir inhibit viral DNA polymerase, reducing viral replication. Topical acyclovir is effective for recurrent herpes labialis, while systemic therapy is reserved for severe mucocutaneous or disseminated infections.

For herpes zoster, early initiation of systemic antivirals shortens the duration of symptoms and reduces the risk of post-herpetic neuralgia [24]. Topical cidofovir and imiquimod have shown promise in resistant viral infections, including molluscum contagiosum and HPV-associated lesions. Imiquimod, an immune response modifier, enhances local interferon production and cytotoxic T-cell activation, making it useful for genital warts and superficial basal cell carcinoma [25]. The choice between systemic and topical antifungal or antiviral therapy depends on infection severity, host immune status, and treatment adherence. The rise of antifungal resistance, particularly azole resistance in *Candida* species, highlights the need for stewardship programs and novel antifungal development.

13.7 Transdermal and Microneedle-Based Delivery

The skin's stratum corneum is a formidable barrier that limits penetration of most therapeutic agents. Traditional topical formulations rely on passive diffusion, which is insufficient for macromolecules and hydrophilic drugs. To overcome this, advanced delivery technologies such as transdermal patches, microneedles, and nanocarrier systems have been developed. Transdermal patches allow sustained drug delivery into systemic circulation by bypassing hepatic first-pass metabolism. While classically used for drugs such as nicotine and fentanyl, research is expanding into dermatologic applications, including hormone delivery, anti-inflammatory agents, and pain management in localized neuropathic conditions [26].

The advantages include steady plasma drug levels, improved patient adherence, and non-invasiveness. However, limited drug candidates restricted to lipophilic, low-molecular-weight molecules remain a constraint. Microneedle-based delivery has emerged as a major innovation. Microneedles, fabricated from biodegradable polymers, metals, or silicon, create microchannels in the stratum corneum, allowing direct passage of drugs, vaccines, or biologics without pain. In dermatology, microneedles are being tested for psoriasis, melanoma vaccines, and cosmetic delivery of peptides and growth factors. Recent clinical studies have shown improved delivery of methotrexate and corticosteroids in localized psoriatic plaques using dissolvable microneedles [27].

Nanotechnology further enhances transdermal delivery. Liposomes, niosomes, ethosomes, and solid lipid nanoparticles increase drug solubility, stability, and penetration. Vesicular carriers encapsulating retinoids and corticosteroids have shown superior efficacy with reduced irritation. Similarly, nanocarriers for antifungals such as terbinafine improve activity against resistant dermatophytes [28]. Despite their promise, regulatory hurdles, manufacturing complexities, and long-term safety remain challenges. Nevertheless, transdermal and microneedle-based systems are poised to play an expanding role in dermatologic therapeutics, particularly for biologics and personalized drug delivery.

13.8 Dermato pharmacovigilance and Safety Monitoring

The long-term use of topical, systemic, and biologic dermatologic therapies necessitates vigilant monitoring of adverse drug reactions (ADRs). Dermato pharmacovigilance is a specialized branch of pharmacovigilance focused on detecting, assessing, and preventing drug-related cutaneous adverse effects. Topical corticosteroids, while effective, may cause local ADRs such as atrophy, telangiectasia, perioral dermatitis, and tachyphylaxis. Systemic absorption can lead to adrenal

suppression, especially in children and elderly patients [29]. Calcineurin inhibitors, though relatively safe, have raised concerns about long-term malignancy risks, though evidence remains inconclusive.

Systemic immunomodulators require stringent laboratory monitoring. Methotrexate necessitates regular liver function and blood counts to detect hepatotoxicity and myelosuppression. Cyclosporine mandates renal monitoring and blood pressure checks due to nephrotoxicity and hypertension. Similarly, apremilast may cause gastrointestinal effects and weight loss requiring patient counseling [30]. Biologic therapies demand specialized safety protocols. Screening for latent tuberculosis, hepatitis B and C, and HIV is mandatory prior to initiation of TNF-α or IL inhibitors. Regular monitoring for infections, malignancies, and autoimmune complications is crucial. Pharmacovigilance databases such as the WHO's VigiBase and FDA's FAERS have identified rare but serious risks, including demyelinating disorders and severe hypersensitivity [31].

Patch testing and hypersensitivity monitoring are critical for cosmetic agents, preservatives, and newer excipients. Long-term effects of nanoparticles and microneedles are under evaluation, emphasizing the need for post-marketing surveillance. Dermato pharmacovigilance thus ensures that therapeutic advances are accompanied by safety vigilance, balancing innovation with risk minimization.

13.9 Cosmetic and Aesthetic Pharmacology

Beyond disease management, dermatologic therapeutics increasingly intersects with cosmetic and aesthetic pharmacology. The demand for minimally invasive procedures, anti-aging interventions, and cosmeceuticals has grown globally, driving innovations that blend pharmacology with aesthetics. Botulinum toxin type A (BoNT-A) is among the most widely used agents in cosmetic dermatology. By inhibiting acetylcholine release at neuromuscular junctions, it induces temporary muscle relaxation, reducing facial wrinkles and dynamic lines. Its safety and efficacy have made it a cornerstone in aesthetic practice. Emerging applications include treatment of hyperhidrosis, rosacea flushing, and oily skin [32].

Dermal fillers, primarily hyaluronic acid-based, restore facial volume, smooth wrinkles, and enhance contours. While generally safe, complications such as vascular occlusion, granuloma formation, and hypersensitivity reactions highlight the need for trained administration and vigilant monitoring. Cosmeceuticals topical agents positioned between cosmetics and pharmaceuticals include antioxidants, peptides, growth factors, and retinoids. Products containing vitamin C, niacinamide, and polyhydroxy acids have gained popularity for anti-aging and pigmentation management. Although marketed as cosmetic agents, their pharmacological activity underscores the importance of evidence-based evaluation [33].

Energy-based devices such as lasers and radiofrequency are increasingly combined with pharmacologic agents for synergistic results. For example, fractional laser-assisted drug delivery enhances penetration of topical retinoids and tranexamic acid in melasma. The growth of cosmetic pharmacology raises ethical and regulatory challenges, particularly concerning safety, over-commercialization, and accessibility. However, its integration into dermatologic therapeutics highlights the evolving role of pharmacology in not only treating disease but also enhancing appearance and quality of life.

Table 13.1: Comparative Overview of Common Dermatologic Therapies

Category	Examples	Mechanism of Action	Key Indications	Major Limitations
Topical corticosteroids	Hydrocortisone, clobetasol	Anti-inflammatory via glucocorticoid receptor binding	Psoriasis, eczema, dermatitis	Atrophy, striae, HPA suppression
Calcineurin inhibitors	Tacrolimus, pimecrolimus	Inhibit T-cell activation and cytokine release	Atopic dermatitis, sensitive areas	Burning, theoretical malignancy risk
Retinoids	Tretinoin, adapalene, isotretinoin	Normalize keratinization, reduce sebum	Acne, photoaging, psoriasis	Irritation, teratogenicity
Biologics	Adalimumab, secukinumab, dupilumab	Target cytokines (TNF, IL-17, IL-4/13)	Psoriasis, atopic dermatitis	Infections, high cost
Antifungals	Terbinafine, ketoconazole	Inhibit ergosterol synthesis	Dermatophytosis, candidiasis	Hepatotoxicity, resistance
Antivirals	Acyclovir, valacyclovir	Inhibit viral DNA polymerase	HSV, VZV	Renal toxicity, resistance

Table 13.2: Emerging Dermatologic Delivery Systems

Delivery System	Principle	Applications	Advantages	Limitations
Transdermal patches	Sustained drug release across skin	Hormones, analgesics	Non-invasive, steady plasma levels	Limited drug candidates
Microneedles	Create microchannels for delivery	Psoriasis, vaccines, cosmetics	Painless, enhances biologic delivery	Regulatory hurdles
Nanocarriers (liposomes, SLNs)	Encapsulation improves penetration	Retinoids, corticosteroids, antifungals	Enhanced efficacy, reduced irritation	Stability, manufacturing cost



Figure 1: Innovative Dermatologic Drug Delivery Approaches

CONCLUSION

Dermatologic therapeutics has evolved from simple topical formulations to a sophisticated integration of systemic immunomodulators, biologics, and advanced drug delivery platforms. The recognition of immunological drivers in psoriasis, eczema, and acne has enabled precision-targeted biologics, while technological advances such as microneedles and nanocarriers promise to overcome long-standing barriers in transdermal delivery. Dermato pharmacovigilance remains central to safe practice, ensuring that therapeutic benefits are not overshadowed by adverse effects. Simultaneously, cosmetic and aesthetic pharmacology reflects the expanding boundaries of dermatologic science, emphasizing not only disease management but also enhancement of quality of life. The future of dermatologic pharmacology lies in personalized medicine, integrating molecular insights with innovative delivery systems to optimize outcomes for diverse patient populations.

REFERENCES

1. Elias PM, Choi EH. Interactions among stratum corneum defensive functions. Exp Dermatol. 2005;14(10):719–726.
2. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
3. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease. J Invest Dermatol. 2014;134(6):1527–1534.
4. Drucker AM, Ellis AG, Bohjanen KA, et al. Systemic immunomodulatory treatments for atopic dermatitis: an evidence-based update. J Am Acad Dermatol. 2020;82(6):1445–1458.
5. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255.
6. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–1122.
7. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2016;74(5):945–973.
8. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51 Suppl 4:2–15.

9. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15.
10. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus. BMJ. 2005;330(7490):516.
11. Kircik LH. Evolving role of topical retinoids in acne management. J Drugs Dermatol. 2016;15(7):s57–s63.
12. Del Rosso JQ, Kim G. Optimizing use of topical antibiotics in acne. Dermatol Clin. 2009;27(1):33–42.
13. Warren RB, Smith CH, Yiu ZZN, et al. Methotrexate in psoriasis: consensus recommendations. Br J Dermatol. 2016;175(1):23–44.
14. Griffiths CE, Dubertret L, Ellis CN, et al. Cyclosporin in psoriasis. Dermatology. 2004;209(3):265-73.
15. Papp K, Reich K, Leonardi CL, et al. Apremilast in psoriasis. Lancet. 2012;380(9843):738–746.
16. Menter A, Strober BE, Kaplan DH, et al. Psoriasis treatment with TNF inhibitors. J Am Acad Dermatol. 2019;80(4):1029–1072.
17. Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and beyond. J Dermatol. 2018;45(6):691–701.
18. Simpson EL, Bieber T, Guttman-Yassky E, et al. Dupilumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.
19. Layton AM. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1(3):162–169.
20. Thiboutot D, Archer DF, Lemay A, et al. Hormonal therapy for acne. J Am Acad Dermatol. 2007;57(6):973–990.
21. Walsh TR, Efthimiou J, Dréno B. Antibiotic resistance in acne. Lancet Infect Dis. 2016;16(3):e23–e33.
22. Schwartz JR, Messenger AG, Tosti A, et al. Seborrheic dermatitis pathogenesis and treatment. J Clin Invest. 2013;123(5):1914–1920.
23. Gupta AK, Versteeg SG, Shear NH. Onychomycosis treatment. J Cutan Med Surg. 2017;21(6):525–536.
24. Whitley RJ. Acyclovir therapy of HSV infections. J Antimicrob Chemother. 1993;32 Suppl A:73–81.
25. Hanna E, Abadi R, Abbas O. Imiquimod in dermatology: an update. J Dermatolog Treat. 2016;27(6):515–523.
26. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov. 2004;3(2):115–124.
27. Ita K. Transdermal delivery of drugs with microneedles: Strategies and outcomes. J Drug Deliv Sci Technol. 2015;29:16–23.
28. Souto EB, Ribeiro AF, Ferreira MI, et al. New nanocarriers for dermal drug delivery. Curr Drug Deliv. 2020;17(5):402–413.
29. Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician. 2009;79(2):135–140.
30. Roelofs AJ, Jones SA.Drug safety monitoring in dermatology. Br J Dermatol. 2018;178(2):307-13.
31. Warren RB, See K, Burden AD, et al. Biologic therapies and safety in psoriasis. J Eur Acad Dermatol Venereol. 2017;31(1):13–19.
32. Carruthers J, Carruthers A. Botulinum toxin in facial aesthetics. Dermatol Clin. 2014;32(1):23-36.
33. Draelos ZD. Cosmeceuticals: Efficacy and safety. Clin Dermatol. 2009;27(5):435–440.